Want to see VANI full AI Analyst Report?
Top Page
Vivani Medical
(NASDAQ:VANI)
Select Model
Select Model
Rating:52Neutral
Price Target:
$1.50
▲(5.63% Upside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance (no revenue, sizeable ongoing losses, and heavy cash burn with meaningful leverage). Offsetting this, technical indicators are moderately positive with the stock trading above key moving averages, and corporate events are favorable given clinical execution milestones and external validation via Novo Nordisk, though valuation remains constrained by lack of profitability and no dividend.
Positive Factors
Clinical execution
Completing the lead obesity trial ahead of schedule demonstrates operational execution and advances NPM-139 toward top-line data, an IND filing and planned Phase 2 development, creating a clearer path for clinical validation.
Negative Factors
No commercial revenue
The absence of revenue confirms that Vivani has not yet commercialized a product and lacks operating leverage. Continued dependence on clinical progress leaves financial performance vulnerable to trial delays or unsuccessful development.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical execution
Completing the lead obesity trial ahead of schedule demonstrates operational execution and advances NPM-139 toward top-line data, an IND filing and planned Phase 2 development, creating a clearer path for clinical validation.
Read all positive factors
Vivani Medical (VANI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$127.64M
Dividend YieldN/A
Average Volume (3M)216.92K
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue GrowthN/A
EPS Growth19.38%
CountryUS
Employees42
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.35
Shares Outstanding90,203,354
10 Day Avg. Volume237,036
30 Day Avg. Volume216,922
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.88
Price to Sales (P/S)0.00
P/FCF Ratio-3.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.83Price Target Upside169.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.33
Revenue Forecast (FY)N/A
Vivani Medical Business Overview & Revenue Model
Company Description
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially com...
How the Company Makes Money
null...
Vivani Medical Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
34
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -130.00K | -424.00K | 0.00 | -357.00K | 0.00 | 0.00 |
| EBITDA | -26.97M | -26.18M | -23.09M | -25.30M | -19.16M | -12.43M |
| Net Income | -26.31M | -26.61M | -23.49M | -25.65M | -13.89M | -12.77M |
Balance Sheet | ||||||
| Total Assets | 41.64M | 39.39M | 41.56M | 45.80M | 51.13M | 5.45M |
| Cash, Cash Equivalents and Short-Term Investments | 19.89M | 16.23M | 18.35M | 20.65M | 45.08M | 2.18M |
| Total Debt | 17.86M | 18.86M | 19.31M | 20.70M | 955.00K | 1.81M |
| Total Liabilities | 22.67M | 23.66M | 23.95M | 25.04M | 6.82M | 2.99M |
| Stockholders Equity | 18.97M | 15.73M | 17.61M | 20.76M | 44.31M | 2.46M |
Cash Flow | ||||||
| Free Cash Flow | -26.50M | -25.49M | -21.34M | -24.59M | -19.13M | -9.20M |
| Operating Cash Flow | -25.30M | -24.32M | -20.79M | -23.70M | -18.79M | -9.19M |
| Investing Cash Flow | -1.20M | -1.17M | -556.00K | -887.00K | -338.00K | -14.00K |
| Financing Cash Flow | 39.09M | 23.27M | 19.05M | 133.00K | 63.39M | 75.62M |
Vivani Medical Technical Analysis
Positive
1.42
Price Trends
1.33
Positive
1.28
Positive
1.29
Positive
Market Momentum
0.02
Negative
55.07
Neutral
46.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VANI, the sentiment is Positive. The current price of 1.42 is above the 20-day moving average (MA) of 1.38, above the 50-day MA of 1.33, and above the 200-day MA of 1.29, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 55.07 is Neutral, neither overbought nor oversold. The STOCH value of 46.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VANI.
Vivani Medical Risk Analysis
Vivani Medical disclosed 65 risk factors in its most recent earnings report. Vivani Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vivani Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $127.64M | -4.00 | -191.05% | ― | ― | 19.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $41.38M | -1.79 | -79.21% | ― | 53.42% | 22.08% | |
46 Neutral | $7.85M | -0.34 | -211.73% | ― | 41.62% | 20.47% | |
42 Neutral | $45.03M | -4.01 | -23.45% | ― | -14.27% | -132.84% |
* Healthcare Sector Average
VANI
Vivani Medical
1.40
0.22
18.64%
NSPR
InspireMD
0.89
-1.53
-63.31%
XTNT
Xtant Medical Holdings
0.33
-0.30
-47.62%
ICCM
Icecure Medical
2.29
-33.41
-93.59%
Vivani Medical Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresM&A TransactionsProduct-Related Announcements
Vivani Speeds Semaglutide Implant Trial Enrollment Completion
Positive
Aug 13, 2026
Vivani Medical reported on August 13, 2026, that it accelerated development of its lead asset NPM-139, a semaglutide implant for chronic weight management, completing ahead of schedule the enrollment and dosing of all 20 participants in its SLIM-1...
Business Operations and StrategyProduct-Related Announcements
Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial
Positive
Aug 6, 2026
On August 6, 2026, Vivani Medical, Inc. reported that its SLIM-1 Phase 1 clinical trial evaluating NPM-139, a miniature subdermal semaglutide implant for chronic weight management, has reached full enrollment and successful initial dosing of all 2...
Business Operations and StrategyProduct-Related Announcements
Vivani Medical Highlights Upcoming SLIM-1 First Dosing Milestone
Positive
Jul 17, 2026
Vivani Medical presented at the Emerging Growth Conference in New York on Wednesday, July 15, 2026, where Chief Executive Officer Dr. Adam Mendelsohn delivered a slide presentation. During the presentation, the company updated investors that the f...
Business Operations and StrategyM&A TransactionsPrivate Placements and FinancingProduct-Related Announcements
Vivani Advances GLP-1 Implant Program With Novo Nordisk
Positive
Jul 7, 2026
On July 1, 2026, Vivani Medical entered into a definitive merger agreement under which its wholly owned subsidiary Cortigent will be merged into a ClearOne subsidiary and become a wholly owned unit of ClearOne. All Cortigent equity held by Vivani ...
Business Operations and StrategyExecutive/Board ChangesProduct-Related AnnouncementsRegulatory Filings and ComplianceShareholder Meetings
Vivani Medical Advances SLIM-1 Trial for Obesity Treatment
Positive
Jun 30, 2026
On June 24, 2026, Vivani Medical held its 2026 Annual Meeting of Stockholders, where shareholders elected six directors to serve until the 2027 meeting, approved on an advisory basis executive compensation, adopted an amended and restated 2022 Omn...
Business Operations and StrategyRegulatory Filings and Compliance
Vivani Medical Highlights Investor Presentation at Jefferies Conference
Neutral
Jun 4, 2026
Vivani Medical, Inc. said it will present at the Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 11:05 a.m. Eastern, with Chief Executive Officer Dr. Adam Mendelsohn scheduled to deliver the slide-based presentatio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.